ATE321133T1 - Polynukleotide enthaltende mittel - Google Patents

Polynukleotide enthaltende mittel

Info

Publication number
ATE321133T1
ATE321133T1 AT95940559T AT95940559T ATE321133T1 AT E321133 T1 ATE321133 T1 AT E321133T1 AT 95940559 T AT95940559 T AT 95940559T AT 95940559 T AT95940559 T AT 95940559T AT E321133 T1 ATE321133 T1 AT E321133T1
Authority
AT
Austria
Prior art keywords
provides
polynucleotide
another aspect
block
polyether
Prior art date
Application number
AT95940559T
Other languages
English (en)
Inventor
Alexander Victorvich Kabanov
Valery Yulievich Alakhov
Sergey V Vinogradov
Original Assignee
Supratek Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supratek Pharma Inc filed Critical Supratek Pharma Inc
Application granted granted Critical
Publication of ATE321133T1 publication Critical patent/ATE321133T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT95940559T 1994-11-18 1995-11-17 Polynukleotide enthaltende mittel ATE321133T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/342,209 US5656611A (en) 1994-11-18 1994-11-18 Polynucleotide compositions

Publications (1)

Publication Number Publication Date
ATE321133T1 true ATE321133T1 (de) 2006-04-15

Family

ID=23340835

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95940559T ATE321133T1 (de) 1994-11-18 1995-11-17 Polynukleotide enthaltende mittel

Country Status (13)

Country Link
US (1) US5656611A (de)
EP (1) EP0789564B1 (de)
JP (1) JPH10509048A (de)
CN (1) CN1173128A (de)
AT (1) ATE321133T1 (de)
AU (1) AU716453B2 (de)
BR (1) BR9509730A (de)
CA (1) CA2205486A1 (de)
DE (1) DE69534895T2 (de)
ES (1) ES2260765T3 (de)
NZ (1) NZ297164A (de)
RU (1) RU2175337C2 (de)
WO (1) WO1996015778A1 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380536A (en) 1990-10-15 1995-01-10 The Board Of Regents, The University Of Texas System Biocompatible microcapsules
US20020123476A1 (en) * 1991-03-19 2002-09-05 Emanuele R. Martin Therapeutic delivery compositions and methods of use thereof
US6933286B2 (en) * 1991-03-19 2005-08-23 R. Martin Emanuele Therapeutic delivery compositions and methods of use thereof
US6277410B1 (en) 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6353055B1 (en) * 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US6359054B1 (en) 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US6743779B1 (en) * 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
JP2690276B2 (ja) * 1995-01-10 1997-12-10 科学技術振興事業団 静電結合型高分子ミセル薬物担体とその薬剤
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
GB9600272D0 (en) * 1996-01-06 1996-03-06 Univ Nottingham Polymers
GB2324534B (en) * 1996-01-06 2000-05-10 Danbiosyst Uk Composition for delivery of nucleic acid to a cell
WO1997040679A1 (en) * 1996-05-01 1997-11-06 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
WO1997045069A1 (en) * 1996-05-29 1997-12-04 Cell Genesys, Inc. Cationic polymer/lipid nucleic acid delivery vehicles
DE19746362A1 (de) * 1996-10-23 1998-04-30 Sueddeutsche Kalkstickstoff Verfahren zur Herstellung von biologisch aktiven Polymernanopartikel-Nucleinsäure-Konjugaten
US5908845A (en) * 1996-10-30 1999-06-01 Segev; David Polyether nucleic acids
GB9623051D0 (en) * 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
CA2298061A1 (en) * 1997-08-01 1999-02-11 Supratek Pharma, Inc. Polynucleotide compositions
US6221425B1 (en) 1998-01-30 2001-04-24 Advanced Cardiovascular Systems, Inc. Lubricious hydrophilic coating for an intracorporeal medical device
EP0963758A3 (de) * 1998-05-07 2000-03-22 Universiteit Gent Synthetische polyamiosaure Komplexen zur Verabreichung von Nukleinsäuren zur Zielzellen
US7396919B1 (en) * 1998-07-17 2008-07-08 Mirus Bio Corporation Charge reversal of polyion complexes
US7375096B1 (en) * 1998-12-04 2008-05-20 California Institute Of Technology Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
GB9913359D0 (en) 1999-06-09 1999-08-11 Cancer Res Campaign Tech Polymer modified biological elements
US6348583B1 (en) * 1999-08-30 2002-02-19 Bio-Rad Laboratories, Inc. Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids
IL150485A0 (en) * 1999-12-28 2002-12-01 Novartis Ag Method of achieving persistent transgene expression
CN101041079A (zh) * 1999-12-30 2007-09-26 诺瓦提斯公司 用于基因治疗的新的胶体合成载体
BR0108959A (pt) * 2000-03-03 2003-10-14 Valentis Inc Composições de polox‰mero ou poloxamina melhoradas para distribuição de ácido nucléico
EP1278551A2 (de) * 2000-04-21 2003-01-29 Vical Incorporated Zusammensetzungen und verfahren zur (in vivo) verabreichung der auf polynukleotiden-basierenden therapeutika
US7256180B2 (en) 2000-04-28 2007-08-14 Supratek Pharma Inc. Compositions and methods for inducing activation of dendritic cells
US20020042388A1 (en) * 2001-05-01 2002-04-11 Cooper Mark J. Lyophilizable and enhanced compacted nucleic acids
CA2411167A1 (en) * 2000-06-23 2002-01-03 Merck & Co., Inc. Polynucleotide vaccine adjuvants and formulations containing cationic surfactants, and methods of use
AU2001290538B2 (en) * 2000-08-18 2005-11-24 University Of North Carolina At Chapel Hill Compositions of nucleic acids that form molten phases and methods of use thereof
AU2001294890A1 (en) 2000-09-25 2002-04-02 Board Of Regents, The University Of Texas System Pei: dna vector formulations for in vitro and in vivo gene delivery
AU2002230058B2 (en) 2001-01-29 2005-11-17 Bio-Rad Laboratories, Inc. Nucleic acid derivatives
WO2002085542A1 (en) * 2001-04-23 2002-10-31 Massachusetts Institute Of Technology Antimicrobial polymeric surfaces
US9089407B2 (en) 2001-04-23 2015-07-28 Massachusetts Institute Of Technology Antibacterial coatings that inhibit biofilm formation on implants
US7151139B2 (en) * 2001-04-23 2006-12-19 Massachusetts Institute Of Technology Antimicrobial polymeric surfaces
US7094810B2 (en) * 2001-06-08 2006-08-22 Labopharm, Inc. pH-sensitive block copolymers for pharmaceutical compositions
US6939564B2 (en) * 2001-06-08 2005-09-06 Labopharm, Inc. Water-soluble stabilized self-assembled polyelectrolytes
EP1421170A2 (de) * 2001-07-31 2004-05-26 CytRx Corporation Zusammensetzungen zur therapeutischen zuführung sowie verfahren zur verwendung davon
EP1448586A4 (de) * 2001-11-02 2006-03-01 Intradigm Corp Therapeutische verfahren für vehikel zur verabreichung von nukleinsäure
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
FR2835749B1 (fr) 2002-02-08 2006-04-14 Inst Nat Sante Rech Med Composition pharmaceutique ameliorant le transfert de gene in vivo
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
EP1480680B1 (de) * 2002-03-07 2010-11-03 Biocompatibles UK Limited Mit nucleinsäure complexierte block-copolymere
US20040102608A1 (en) * 2002-05-13 2004-05-27 Cornell Research Foundation, Inc. Multiblock copolymers having improved mechanical properties
AR037006A1 (es) * 2002-06-20 2004-10-20 S I G Sist S De Identificacion Marcador de objetos a identificar consistente en al menos un fragmento de adn.
CN102516417B (zh) 2002-09-06 2014-12-10 天蓝制药公司 用于传递治疗剂的以环糊精为基础的聚合物
WO2004060059A2 (en) * 2002-12-23 2004-07-22 Vical Incorporated Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
CA2756797C (en) 2002-12-23 2015-05-05 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
CA2508281C (en) * 2002-12-23 2011-08-09 Vical Incorporated Method for producing sterile polynucleotide based medicaments
US7682626B2 (en) * 2003-02-07 2010-03-23 Roche Madison Inc. Polyvinylethers for delivery of polynucleotides to mammalian cells
EP1620450A4 (de) * 2003-04-13 2011-01-19 Enzon Pharmaceuticals Inc Polymere oligonukleotid-prodrugs
US8080642B2 (en) 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
JP4763459B2 (ja) * 2003-05-29 2011-08-31 株式会社東京大学Ｔｌｏ 安定化高分子ミセル
EP1518568B1 (de) * 2003-09-25 2009-05-27 Wageningen Universiteit, Agrotechnologie en Voedingswetenschappen Mizellen mit einem Komplexkoazervatkern als fäulnishemmende Mittel
US7985424B2 (en) 2004-04-20 2011-07-26 Dendritic Nanotechnologies Inc. Dendritic polymers with enhanced amplification and interior functionality
BRPI0510093B8 (pt) * 2004-04-20 2022-12-27 Dendritic Nanotechnologies Inc polímeros dendríticos
US20060024670A1 (en) * 2004-05-18 2006-02-02 Luke Catherine J Influenza virus vaccine composition and methods of use
US7422875B2 (en) 2004-07-20 2008-09-09 Board Of Regents Of The University Of Nebraska Compositions and methods for increasing protein production
EP1804813A4 (de) * 2004-09-27 2011-09-07 Vical Inc Formulierungen und verfahren zur behandlung von entzündlichen erkrankungen
US20060134221A1 (en) * 2004-12-03 2006-06-22 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
US20060276371A1 (en) * 2005-06-01 2006-12-07 Anthony Schreiner Coacervate systems having soil anti-adhesion and anti-deposition properties on hydrophilic surfaces
EP1904111A4 (de) 2005-06-03 2009-08-19 Univ Johns Hopkins Zusammensetzungen und verfahren zur verringerung der microrna-expression zur behandlung von neoplasien
CN101370817B (zh) * 2005-12-15 2012-08-08 国立科学研究中心 阳离子寡核苷酸、制备阳离子寡核苷酸的自动化方法及其用途
BRPI0716890A2 (pt) * 2006-09-22 2013-10-22 Labopharm Inc Composição, e, método de produção de uma composição, de administração de um agente farmaceuticamente ativo insolúvel em água a um mamífero, e de tratamento de câncer em um mamífero
CN101627092A (zh) * 2006-11-08 2010-01-13 麻省理工学院 使病毒和细菌失活的聚合涂料
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
WO2008141275A1 (en) 2007-05-11 2008-11-20 The Johns Hopkins University Biomarkers for melanoma
US20110229498A1 (en) 2008-05-08 2011-09-22 The Johns Hopkins University Compositions and methods for modulating an immune response
KR20110095292A (ko) * 2008-11-06 2011-08-24 유니버시티 오브 워싱톤 다중블록 공중합체
EA201200617A1 (ru) * 2009-11-23 2012-11-30 Серулин Фарма Инк. Полимеры на основе циклодекстрина для доставки лекарственных средств
WO2011143651A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
BR112012029057A2 (pt) 2010-05-14 2020-10-13 Dana-Farber Cancer Institute, Inc. composições e métodos de tratamento de leucemia
US9320814B2 (en) * 2011-11-01 2016-04-26 Board Of Regents Of The University Of Nebraska Polyplexes of hydrophobically-modified siRNA for delivery of siRNA
EP2780455B1 (de) 2011-11-17 2017-07-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Therapeutische chimäre rna/dna-nanopartikel (np) mit automatischer erkennung
JP2014533953A (ja) 2011-11-17 2014-12-18 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 治療用ｒｎａスイッチ組成物及び使用方法
WO2013106358A1 (en) 2012-01-10 2013-07-18 Hussain M Mahmood Method of treating hyperlipidemia and atherosclerosis with mir-30c
WO2013177473A1 (en) 2012-05-25 2013-11-28 The University Of Vermont And State Agriculture College Compositions and methods for assaying platelet reactivity and treatment selection
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
EP3034539A1 (de) * 2014-12-19 2016-06-22 Ethris GmbH Zusammensetzungen zur Einführung von Nukleinsäure in Zellen
EP3373939A4 (de) 2015-11-10 2019-06-26 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University Mittel und verfahren zur verringerung der tumorigenität von krebsstammzellen
CN108601951B (zh) 2015-12-09 2022-11-22 金港医疗(澳大利亚)私人有限公司 用于治疗的免疫调节组合物
EP3386594B1 (de) 2015-12-11 2023-05-03 The General Hospital Corporation Kombination eines hemmer des pdgf-a rezeptors hemmers und eines hemmer der histon-lysin-demethylase zur behandlung arzneimitteltoleranter glioblastom
KR20200141470A (ko) 2018-04-06 2020-12-18 칠드런'즈 메디컬 센터 코포레이션 체세포 재프로그래밍 및 각인의 조정을 위한 조성물 및 방법
JP2023530234A (ja) 2020-06-05 2023-07-14 ザ・ブロード・インスティテュート・インコーポレイテッド 新生物を治療するための組成物および方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5944489A (ja) * 1982-09-07 1984-03-12 帝国石油株式会社 原油回収用ミセル溶液組成物
US5041288A (en) * 1986-05-15 1991-08-20 Emory University Method of treating tissue damaged by reperfusion injury
US4801452A (en) * 1986-05-15 1989-01-31 Hunter Robert L Fibrinolytic composition
US5030448A (en) * 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US5047236A (en) * 1986-05-15 1991-09-10 Emory University Method of treating stroke
US4873083A (en) * 1986-05-15 1989-10-10 Emory University Fibrinolytic composition
US4879109A (en) * 1986-05-15 1989-11-07 Emory University Method for treating burns
US5017370A (en) * 1986-05-15 1991-05-21 Emory University Improved method of performing angioplasty procedures
EP0262516A2 (de) * 1986-09-29 1988-04-06 Miles Inc. Genetische Transformation von Milchsäurebakterien
WO1993008845A1 (en) * 1991-11-08 1993-05-13 Massachusetts Institute Of Technology Localized oligonucleotide therapy
AU8076494A (en) * 1993-10-15 1995-05-04 Cytrx Corporation Therapeutic delivery compositions and methods of use thereof

Also Published As

Publication number Publication date
DE69534895D1 (de) 2006-05-11
EP0789564A1 (de) 1997-08-20
AU4196596A (en) 1996-06-17
CA2205486A1 (en) 1996-05-30
DE69534895T2 (de) 2006-11-09
WO1996015778A1 (en) 1996-05-30
NZ297164A (en) 2000-01-28
AU716453B2 (en) 2000-02-24
BR9509730A (pt) 1997-09-30
ES2260765T3 (es) 2006-11-01
EP0789564A4 (de) 2000-11-08
RU2175337C2 (ru) 2001-10-27
CN1173128A (zh) 1998-02-11
EP0789564B1 (de) 2006-03-22
US5656611A (en) 1997-08-12
JPH10509048A (ja) 1998-09-08

Similar Documents

Publication Publication Date Title
ATE321133T1 (de) Polynukleotide enthaltende mittel
EP1439195A3 (de) Wasserlösliche Polymere mit niedrigem Gehalt von Restmonomeren und deren Verwendung
BR9911754A (pt) Copolìmero linear de ciclodextrina, composição terapêutica, composição de ciclodextrina, processos de preparo de um copolìmero linear de ciclodextrina, e de um copolìmero linear de ciclodextrina oxidada, processo para produzir um polìmero reticulado de ciclodextrina, e, processo de tratamento
CA2173878A1 (en) Polynucleotide for Treating Systemic Lupus Erythematosus
DE69630615D1 (de) Verwendung einer zusammensetzung enthaltend polyether block copolymere
AU1843792A (en) Composition for washing and/or conditioning keratinous matter, containing a silicone and an amphoteric polymer derived from diallyldialkylammonium and from an anionic monomer
DE3682420D1 (de) Acrylatemulsionspolymere als verdickungsmittel in waessrigen systemen und copolymerisierbare monomere emulgiermittel verwendbar in diesen copolymeren.
DE69718802D1 (de) Supramolekular polymere
DE3765146D1 (de) Vernetzte karboxylgruppen enthaltende kopolymere, verwendbar als verdickungsmittel in waessrigen systemen und deren herstellung.
ES2005574A6 (es) Procedimiento para preparar un agente espesante y una composicion cosmetica que lo contiene.
BR8406665A (pt) Composicao de polimero compatibilizada e copolimero de enxerto
ES2189249T3 (es) Com`posiciones polimeras acuosas estables que contienen poli(alquileniminas).
FR2737659B1 (fr) Composition cosmetique contenant une dispersion aqueuse de polymere et une silicone insoluble, utilisation et procede
MX9206247A (es) Agentes de transferencia de cadena de mercaptano latentes de tiol y su empleo en la sintesis de polimeros.
CA2138314A1 (en) Acrylamide Polymers and Use Thereof
DE69317768D1 (de) Vollaromatische flüssigkristalline polymere, die ionische monomereinheiten enthalten und verbundstoffe daraus
FR2761599B1 (fr) Compositions cosmetiques contenant un polymere cationique de faible masse moleculaire et leurs utilisations
CA2301711A1 (en) Lipid-containing compositions and uses thereof
DE69708304D1 (de) Vernetzte copolymere auf der basis von polycarbonsäurepolymeren
ES2005009A6 (es) Gel dentifrico.
ZA979572B (en) Conditioning shampoo compositions containing emulsion polymerized polymers.
EP0416496A3 (en) Blends of carbonate polymer, polyacetal and compatibilizer
FR2769316B1 (fr) Copolymere greffe par polymerisation radicalaire en presence de radicaux stables, sa preparation et ses applications
NO992604L (no) Oppbygningsundertrykkende midler, blandinger inneholdende slike midler og anvendelse derav i polymeriseringsprosessen
WO1997049718A3 (fr) Conjugues d'un oligonucleotide/polymere conducteur electronique avec une molecule d'interet, et leurs utilisations

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties